-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S.

--Vepdegestrant是一种针对嵌合体（PROTAC®）蛋白降解剂的研究性蛋白水解剂，旨在靶向和降解雌激素受体（ER）蛋白——康涅狄格州纽黑文和纽约，2024年2月6日（环球通讯社）——Arvinas，Inc.（纳斯达克股票代码：ARVN）和辉瑞公司（纽约证券交易所代码：PFE）今天宣布，美国。

Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.

美国食品和药物管理局（FDA）已经批准了vepdegestrant（ARV-471）单药治疗雌激素受体（ER）阳性/人生长表皮生长因子2（HER2）阴性（ER+/HER2-）成人的快速通道指定，用于研究先前接受内分泌治疗的局部晚期或转移性乳腺癌。

Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer. As described by the FDA, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Vepdegestrant是一种新型口服蛋白水解靶向嵌合体（PROTAC®）ER降解剂，由Arvinas和辉瑞公司联合开发。正如FDA所描述的那样，快速通道是一个旨在促进开发和加速药物审查的过程，以治疗严重疾病并满足未满足的医疗需求。

The purpose is to get important new drugs to patients earlier. Vepdegestrant as a monotherapy is being studied in the ongoing Phase 3 VERITAC-2 clinical trial, which is evaluating vepdegestrant or fulvestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer who have been previously treated with an endocrine-based therapy.

目的是尽早向患者提供重要的新药。Vepdegestrant作为一种单一疗法正在正在进行的3期VERITAC-2临床试验中进行研究，该试验正在评估Vepdegestrant或氟维司群治疗局部晚期或转移性ER+/HER2乳腺癌患者，这些患者以前曾接受过内分泌治疗。

'We are focused on the persisting unmet needs of people with ER+/HER2- breast cancer and doing all that we can to expedite the development of vepdegestrant as a novel, oral ER-targeted potential therapy for this patient community,” said John Houston, Ph.D., Arvinas Chairperson, Chief Executive Officer, and President.

“我们专注于ER+/HER2乳腺癌患者持续未满足的需求，并尽一切努力加快vepdegestrant的发展，作为针对该患者社区的新型口服ER靶向潜在疗法，”约翰·休斯顿博士，Arvinas主席，首席执行官兼总裁说。

“We are pleased the FDA has granted Fast Track designation for vepdegestrant, and we continue to believe this investigational drug has th.

“我们很高兴FDA批准了vepdegestrant的快速通道，我们仍然相信这种研究药物具有th。